HomeIngredientCo-encapsulation of Curcumin and Boswellic Acids in Chitosan-Coated Niosome: An In-vitro Digestion Study

Co-encapsulation of Curcumin and Boswellic Acids in Chitosan-Coated Niosome: An In-vitro Digestion Study

April 24, 2022

J Microencapsul. 2022 Apr 6:1-36. doi: 10.1080/02652048.2022.2060360. Online ahead of print.

ABSTRACT

AIM: In this study chitosan-coated niosome (ChN) was utilized for bioavailability enhancement of curcumin (Cn) and boswellic acids (BAs).

METHODS: The bare niosome (BN) was prepared by the heating method and optimized by using the mixture design procedure. Physicochemical stability, as well as the in vitro release, and bioavailability of Cn and BAs in BN and ChN were studied.

RESULTS: The optimized BN had a mean diameter of 70.00 ± 0.21 nm and surface charge of -31.00 ± 0.25 mv, which changed to 60.01 ± 0.20 nm and +40.00 ± 0, respectively, in ChN. In-vitro digestion study revealed chitosan layer augmented the bioavailability of Cn and BAs to 79.02 ± 0.13 and 81 ± 0.10, respectively. The chitosan layer obviously improved the physical stability of Cn and BA in the niosome vehicle, by means of vesicle size, zeta potential, and encapsulation efficiency.

CONCLUSION: The Chitosan-coated niosome was considered to be promising delivery system for increasing the bioavailability of Cn and BAs.

PMID:35384786 | DOI:10.1080/02652048.2022.2060360

Tags:,

Related Posts

About The Author

Patrick Blanchard MD

Meet Dr. Blanchard Dr. Blanchard’s medical practice is an embodiment of Integrative health which brings conventional and complementary approaches together in a coordinated way. Conveniently located in sunny Florida and over the internet with ValiseMD’s secure HIPPA compliant telXmed servers. Since 1994, patients with a wide range of challenging medical problems have achieved optimum health using the best of natural medicine, judiciously combined with high-tech innovations. Breakthroughs are often achieved even after patients have consulted mainstream specialists and holistic practitioners. Dr. Blanchard is founder and CEO of ValiseMD, Inc. He is board certified in Family Medicine since 1994 and awarded Fellow of the American Academy of Family Physicians in 2001. He received the ‘Teacher of the Year’ award from the University of Kansas School of Medicine at completion of his residency in Family Medicine. He completed a fellowship at Wake Forest University in the field of vascular neurosonology. He holds a medical patent in the field of Gastroenterology. He holds an unrestricted license to practice medicine and surgery in Florida. He started his medical career as a Emergency Medical Technician, then as a Paramedic and later a Medical Doctor.